Pretargeting: Bridging the Two Worlds of Radiopharmaceutical Probes

Area of Science:

• Oncology
• Radiochemistry
• Immunology

Background:

• The human trophoblast cell-surface antigen 2 (Trop-2) is a protein frequently overexpressed in various types of cancer.
• Trop-2 plays a role in tumor progression and is a target for cancer therapies.

Purpose of the Study:

• To develop and evaluate a novel radiolabeled antibody targeting Trop-2 using pretargeting methodology.
• To assess the potential of this agent for cancer imaging and theranostics in a preclinical setting.

Main Methods:

• Development of a novel antibody against Trop-2.
• Radiolabeling of the antibody.
• Evaluation of the radiolabeled antibody in a preclinical model using pretargeting techniques.

Main Results:

• The novel Trop-2 antibody demonstrated promising characteristics in preclinical evaluations.
• The pretargeting methodology facilitated effective delivery and retention of the radiolabeled agent.

Conclusions:

• The radiolabeled Trop-2 antibody is a potential candidate for further clinical development.
• This agent shows promise as both an imaging agent and a theranostic tool for Trop-2-expressing malignancies.